Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly (LLY) stock recovers as company executives seize a rare buying opportunity to make a series of insider purchases ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...